- Results suggest ceftaroline is a safe and effective therapeutic alternative for patients with community-acquired pneumonia (CAP) or complicated skin and skin structure infections (cSSSI), but it should currently be reserved as an alternative rather than first-line option.
Why this matters
- Early, widespread use of ceftaroline may promote resistance, and current evidence calls for more conservative conclusions regarding its place in therapy.
- Systematic review and meta-analysis comparing efficacy and safety of ceftaroline vs standard antibiotic regimens for CAP and cSSSIs.
- Funding: None.
- 3 randomized controlled trials per indication.
- Comparator agents: Ceftriaxone in CAP and vancomycin plus aztreonam in cSSSI.
- In CAP (n=2011), ceftaroline was statistically significantly more efficacious for clinical cure compared to ceftriaxone (risk ratio [RR], 1.11).
- In cSSSI (n=1496), no statistically significant difference in clinical cure between ceftaroline and comparator regimen (RR, 1.01).
- No statistically significant difference in mortality for either indication.
- No major findings for safety outcomes.
- Risk for industry influence was high among studies included in meta-analysis.
- Possible selective outcome reporting bias.